Recombinant IL23A (Risankizumab Biosimilar) antibody
Quick Overview for Recombinant IL23A (Risankizumab Biosimilar) antibody (ABIN7676025)
Target
Antibody Type
Reactivity
Host
Clonality
Conjugate
Application
-
-
Expression System
- CHO Cells
-
Purpose
- Anti-IL-23a Reference Antibody (risankizumab)
-
Sequence
- QVQLVQSGAE VKKPGSSVKV SCKASGYTFT DQTIHWMRQA PGQGLEWIGY IYPRDDSPKY NENFKGKVTI TADKSTSTAY MELSSLRSED TAVYYCAIPD RSGYAWFIYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKRVEP KSCDKTHTCP PCPAPEAAGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSREE MTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG,DIQMTQSPSS LSASVGDRVT ITCKASRDVA IAVAWYQQKP GKVPKLLIYW ASTRHTGVPS RFSGSGSRTD FTLTISSLQP EDVADYFCHQ YSSYPFTFGS GTKLEIKRTV AAPSVFIFPP SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
-
Characteristics
- Anti-IL-23a Reference Antibody (risankizumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
Purity
- >95 %
-
Isotype
- IgG1
-
-
-
-
Application Notes
- Optimal working dilution should be determined by the investigator.
-
Comment
-
Therapeutic Agents by Target and Mechanism: IL-23p19 inhibitors
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Concentration
- 1 mg/mL
-
Buffer
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
Storage
- 4 °C,-80 °C
-
Storage Comment
- +4°C,-80°C
-
-
- IL23A (Risankizumab Biosimilar)
-
Alternative Name
- IL-23a (Risankizumab Biosimilar)
-
Target Type
- Biosimilar
-
Molecular Weight
- 145.5 kDa
-
UniProt
- Q9NPF7
Target
-